Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 2/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 16/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.60 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | NPY4R | P50391 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13796916 | 0.90 | AQP1 (0.64) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL13795948 | 0.90 | AQP1 (0.69) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL13796241 | 0.90 | AQP1 (0.63) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL13796949 | 0.89 | AQP1 (0.65) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL13796884 | 0.89 | NPY5R (0.61) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL14606607 | 0.88 | NPY5R (0.60) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL13796880 | 0.88 | NPY5R (0.60) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL13796973 | 0.88 | AQP1 (0.66) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL13796834 | 0.87 | AQP1 (0.55) | AQP1NPY5RADRA2AMCHR1ALDH1A1 | |
| SCHEMBL13796843 | 0.87 | AQP1 (0.53) | AQP1NPY5RADRA2AMCHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-7544690-B2 | MCH receptor antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037836-A1 | Melanin concentrating hormone; obesity and related disorders, anxiety, or depression; trans-4-Bromo-N-{4-[(4-dimethylamino-quinazolin-2-ylamino)-methyl]-cyclohexylmethyl}-2-trifluoromethoxy-benzenesulfonamide | MCHR1, MCHR2, MC4R | AQP1 2957/4885NPY5R 11/4885ADRA2A 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.